Drug Discovery Today

1

Translation of drug effects from experimental models of neuropathic pain and analgesia to humans

Amit Taneja, Vincenzo Luca Di Iorio, Meindert Danhof, Oscar Della Pasqua

Journal:

Année:

2012

Langue:

english

Fichier:

PDF, 1.55 MB

english, 2012

2

R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies

Nicola Dimitri

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 214 KB

english, 2012

3

Cell-penetrating peptides: classes, origin, and current landscape

Francesca Milletti

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 440 KB

english, 2012

4

Microtissue size and hypoxia in HTS with 3D cultures

Amish Asthana, William S. Kisaalita

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 683 KB

english, 2012

5

Biologics: the next generation of analgesic drugs?

Iain P. Chessell, Amanda Dudley, Andy Billinton

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 184 KB

english, 2012

6

Strategic alliances and market risk

Matthias Havenaar, Peter Hiscocks

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 206 KB

english, 2012

7

Fluorine local environment: from screening to drug design

Anna Vulpetti, Claudio Dalvit

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 845 KB

english, 2012

8

Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

Li Di, Per Artursson, Alex Avdeef, Gerhard F. Ecker, Bernard Faller, Holger Fischer, J. Brian Houston, Manfred Kansy, Edward H. Kerns, Stefanie D. Krämer, Hans Lennernäs, Kiyohiko Sugano

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 518 KB

english, 2012

9

Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure

John Higgins, Mark E. Cartwright, Allen C. Templeton

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 546 KB

english, 2012

10

Physiological, pathological and potential therapeutic roles of adipokines

Inês Falcão-Pires, Paulo Castro-Chaves, Daniela Miranda-Silva, André P. Lourenço, Adelino F. Leite-Moreira

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 670 KB

english, 2012

11

DNA polymerase beta (pol β) inhibitors: A comprehensive overview

Khaled H. Barakat, Melissa M. Gajewski, Jack A. Tuszynski

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 747 KB

english, 2012

12

Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries

Aruni S. Arachchige Don, Chi Kwan Tsang, Tatiana M. Kazdoba, Gabriella D’Arcangelo, Wise Young, X.F. Steven Zheng

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 909 KB

english, 2012

13

Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010

Anne R. Pariser, Daniel J. Slack, Larry J. Bauer, Catherine A. Warner, LaRee A. Tracy

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 252 KB

english, 2012

14

Network analysis has diverse roles in drug discovery

Samiul Hasan, Bhushan K. Bonde, Natalie S. Buchan, Matthew D. Hall

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 236 KB

english, 2012

15

Can network pharmacology rescue neutraceutical cancer research?

Asfar S. Azmi, Ramzi M. Mohammad, Fazlul H. Sarkar

Journal:

Drug Discovery Today

Année:

2012

Langue:

english

Fichier:

PDF, 170 KB

english, 2012

16

Volume 17; Issue 15-16

Translation of drug effects from experimental models of neuropathic pain and analgesia to humans

R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies

Cell-penetrating peptides: classes, origin, and current landscape

Microtissue size and hypoxia in HTS with 3D cultures

Biologics: the next generation of analgesic drugs?

Strategic alliances and market risk

Fluorine local environment: from screening to drug design

Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure

Physiological, pathological and potential therapeutic roles of adipokines

DNA polymerase beta (pol β) inhibitors: A comprehensive overview

Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries

Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010

Network analysis has diverse roles in drug discovery

Can network pharmacology rescue neutraceutical cancer research?

Contents

Contents